Sun Pharma Gets Global Ex-US and China Rights to Lerodalcibep from Lib Therapeutics

Market snapshot: Sun Pharmaceutical Industries Limited has entered a global licensing and commercialisation agreement with LIB Therapeutics Inc. for lerodalcibep, branded as Lyrokaul in the EU. This strategic expansion targets a massive lipid-lowering market outside the United States and China. The therapy recently received approval from the European Commission on September 21, 2026.

Data Snapshot

• The ex-US/China PCSK9 inhibitor market is valued at US$3.7 billion as of MAT Q2 2026, growing at a compound annual growth rate (CAGR) of 38%.
• Europe represents the largest portion of this addressable market, accounting for US$2.9 billion as of Q2 2026.
• In its Q1 FY27, Sun Pharma reported a consolidated net profit of ₹2,894.8 crore, a 27.08% year-on-year increase from ₹2,278.6 crore in Q1 FY26.

What's Changed

• The agreement provides Sun Pharma with direct entry into the high-potential lipid-lowering therapies market in Europe and other international markets (excluding the US and China).
• The licensing deal shifts Sun Pharma's innovative pipeline focus further into cardiovascular treatments, capitalizing on the recent September 21, 2026, European approval of lerodalcibep (Lyrokaul).

Key Takeaways

• Sun Pharma secures exclusive rights to manufacture and commercialise the novel biologic lerodalcibep in international territories excluding the US and China.
• The ex-US/China PCSK9 inhibitor market was valued at US$3.7 billion as of MAT Q2 2026, with Europe representing the largest territory at US$2.9 billion.
• Lerodalcibep was approved in the European Union on September 21, 2026, and offers a highly competitive 6-month room-temperature stability profile.
• LIB Therapeutics remains eligible for upfront payments, future milestones, and sales royalties, although the exact deal value remains confidential.

SAHI Perspective

This deal underscores Sun Pharma's disciplined approach to building its specialty portfolio. By bypassing the highly competitive and cost-intensive US and China territories, the company targets a rapidly expanding US$3.7 billion ex-US/China market. The 6-month ambient room-temperature storage capability of Lyrokaul provides a distinct convenience advantage over legacy refrigerated PCSK9 inhibitors, making it highly attractive for out-of-hospital use and potentially accelerating clinical adoption.

Market Implications

The entry into European and other emerging market cardiovascular spaces will diversify Sun Pharma's specialty revenue. While near-term R&D or milestone payout obligations may marginally increase operating outlays, the long-term, high-margin profile of novel biologics is structurally positive for the company's consolidated EBITDA margin. It strengthens Sun Pharma's global positioning as a specialty pharmaceutical player.

Trading Signals

Market Bias: Bullish

Sun Pharma's entry into the ex-US/China PCSK9 inhibitor market, valued at US$3.7 billion and growing at a 38% CAGR, significantly enhances its innovative segment. Supported by solid domestic growth of 16% in Q1 FY27, this deal secures a new specialty growth driver.

Overweight: Pharmaceuticals, Healthcare

Trigger Factors:

• Receipt of regulatory clearances and product registration in target emerging markets.
• Dissemination of financial structures (upfront and milestone outlays) in subsequent quarters.
• Actual launch velocity and distribution partnerships established in European countries.

Time Horizon: Medium-term (3-12 months)

Industry Context

The global lipid-lowering market is evolving rapidly as clinical guidelines lower low-density lipoprotein cholesterol (LDL-C) targets for high-risk cardiac patients. In Europe, observational trials like DA VINCI indicate that only 33% of high-risk patients successfully reach target LDL-C goals despite receiving stable oral therapies. Biologics like lerodalcibep address this massive clinical gap, competing with established therapies such as Amgen's Repatha and Sanofi's Praluent.

Key Risks to Watch

• Launch and market penetration risks in highly heterogeneous European and emerging markets.
• Potential near-term margin dilution depending on the scale and amortization of upfront/milestone payouts to LIB.
• Competitive pricing pressures from existing PCSK9 monoclonal antibodies and newer small-interfering RNA (siRNA) therapies.

Recent Developments

Sun Pharma's Q1 FY27 consolidated net profit rose 27.08% YoY to ₹2,894.8 crore (adjusted net profit was ₹3,089.4 crore), driven by 16% YoY growth in India formulation sales. In addition, the remote e-voting for reclassifying Mr. Sudhir Valia and two other family members (holding a collective 1.80% stake) from the promoter group to the public category successfully concluded on September 26, 2026.

Closing Insight

By systematically leveraging robust domestic cash flows to secure under-penetrated international specialty rights, Sun Pharma is successfully decoupling its growth from the price-sensitive US generic market. The addition of lerodalcibep positions the company at the forefront of global lipid-management innovation.

High Performance Trading with SAHI.